Sherry Chen

Rapid Improvement in Skin Pain Severity and Its Impact on Quality of Life in Adult Patients With Moderate-to-Severe Atopic Dermatitis From a Double-Blind, Placebo-Controlled Baricitinib Phase 3 Study

J. Thyssen, L. Strowd, M. Casillas, 2022, Journal of cutaneous medicine and surgery.

Use of white matter reference regions for detection of change in florbetapir positron emission tomography from completed phase 3 solanezumab trials

M. Mintun, A. Fleisher, E. Siemers, 2017, Alzheimer's & Dementia.

Baricitinib Rapidly Improves Skin Pain Resulting in Improved Quality of Life for Patients with Atopic Dermatitis: Analyses from BREEZE-AD1, 2, and 7

T. Buhl, J. Thyssen, S. Ständer, 2021, Dermatology and Therapy.

Itch and Sleep Improvements with Baricitinib in Patients with Atopic Dermatitis: A Post Hoc Analysis of 3 Phase 3 Studies

T. Buhl, E. Serra‐Baldrich, P. Fernández-Peñas, 2021, Dermatology and Therapy.

Onset of Symptom Relief Reported in Daily Diaries of Patients With Atopic Dermatitis Treated With Baricitinib in a United States Clinical Trial (BREEZE-AD5)

M. Casillas, D. Rosmarin, Stacy R. Smith, 2022, Journal of cutaneous medicine and surgery.

Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3.

J. Silverberg, E. Simpson, K. Reich, 2022, The British journal of dermatology.

Lebrikizumab Improves Quality of Life and Patient-Reported Symptoms of Anxiety and Depression in Patients with Moderate-to-Severe Atopic Dermatitis

H. Sofen, Sherry Chen, E. Pierce, 2024, Dermatology and therapy.